Tailor-made vaccine hailed as milestone in renal-cell cancer

A new vaccine obtained from the patient’s own tumour tissue may offer the first effective adjuvant treatment for renal-cell carcinoma following surgery. The findings of the phase III clinical trial are being hailed as a breakthrough in immunology therapy.

Be the first to comment

Leave a Reply

Your email address will not be published.